By Cara Murez
WEDNESDAY, Nov. 4, 2020 (HealthDay Information) — A brand new immunotherapy that has proven success towards multiple sclerosis in animals could possibly be promising for people, a brand new examine suggests.
Researchers at Thomas Jefferson College in Philadelphia are learning a drug that may stop immune system cells from attacking the myelin sheath, a protecting layer that surrounds nerve cells. With MS, the physique’s immune system assaults the central nervous system by attacking the myelin sheath.
Whereas this remedy would impede the autoimmune response, it might go away the remainder of the immune system totally functioning, in keeping with the examine.
“It is a large benefit of our antigen-specific technique over present therapies, that are like a sledgehammer to the immune system,” stated senior examine creator Dr. Abdolmohamad Rostami, chairman of the Division of Neurology at Sidney Kimmel Medical Faculty at Thomas Jefferson College.
“There are lots of potential immune-activating antigens within the myelin sheath, however the greatest hurdle is that we do not know which element of myelin is triggering the immune response in MS sufferers,” Rostami defined. “Earlier research have used single myelin antigens or mixtures of antigens to stop autoimmunity in animal fashions, however in people they’ve had restricted success.”
For this examine, researchers checked out cells known as oligodendrocytes, which wrap their cell membrane round nerve cells to supply the myelin sheath. Scientists can harvest tiny sacs known as extracellular vesicles (EVs) from these cultured cells. Researchers imagine these EVs comprise all of the related myelin antigens, which suggests there can be the next probability they might cease the autoimmune assault on myelin.
“The neat factor about these EVs is that they offer us a possibility to deal with the illness in an antigen-specific manner, with out having to know the precise id of the goal antigen,” Rostami stated in a college information launch. “It covers all of the bases.”
Researchers injected these EVs into three completely different mouse fashions meant to indicate impression on MS at each early and late levels. They reported that it prevented onset of signs like decreased mobility and paralysis when administered earlier than the illness developed, in addition to decreasing severity of illness when given later.
That this method was efficient in several fashions suggests this might act as a common remedy, Rostami famous. Nonetheless, outcomes from animal research don’t at all times pan out in people.
The researchers stated they have been additionally in a position to isolate EVs from human cells, discovering in addition they contained a number of myelin antigens. It is potential that they might have the identical therapeutic impact in sufferers, in keeping with the examine.
Rostami and his workforce are engaged on patenting the intravenous EVs method.
The examine was printed Nov. 4 in Science Translational Drugs.
Go to the Nationwide A number of Sclerosis Society to study extra about treatments for MS.
SOURCE: Thomas Jefferson College, information launch, Nov. 3, 2020